Literature DB >> 18809585

Bevacizumab in advanced cancer, too much or too little?

A Jirillo, F Vascon, M Giacobbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18809585     DOI： 10.1093/annonc/mdn564

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  The effect of care setting in the delivery of high-value colon cancer care.

Authors:  Christine M Veenstra; Andrew J Epstein; Kaijun Liao; Arden M Morris; Craig E Pollack; Katrina A Armstrong
Journal:  Cancer       Date:  2014-06-20       Impact factor: 6.860

2.  Contraindicated use of bevacizumab and toxicity in elderly patients with cancer.

Authors:  Dawn L Hershman; Jason D Wright; Emerson Lim; Donna L Buono; Wei Yann Tsai; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 3.  Tumor-stromal interactions in pancreatic cancer.

Authors:  Clifford Whatcott; Haiyong Han; Richard G Posner; Daniel D Von Hoff
Journal:  Crit Rev Oncog       Date:  2013

Review 4.  After counterfeit Avastin®--what have we learned and what can be done?

Authors:  Tim K Mackey; Raphael Cuomo; Camille Guerra; Bryan A Liang
Journal:  Nat Rev Clin Oncol       Date:  2015-03-03       Impact factor: 66.675

Review 5.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

6.  Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.

Authors:  Bishal Gyawali; Mahesh Iddawela
Journal:  J Glob Oncol       Date:  2016-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.